Company intelligence / Profile preview

Graphium Biosciences

Cleveland, Ohio, United Statesgraphiumbio.com ↗

Ownership: Private
Development stage: Other

Overview

Graphium’s lead candidate, VBX‑100—a glycosylated THC molecule—has shown positive efficacy in two industry-standard colitis models in animals. It has received FDA Orphan Drug Designation for pediatric ulcerative colitis. Multiple compounds have been tested in mouse, rat, and monkey studies. No clinical trial results are available yet.

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: Small moleculeGlycosylated cannabinoid
Industry: Biotech

Drug pipeline

1 asset

VBX-100

Unknown

Beyond the preview

Go deeper on Graphium Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Graphium Biosciences.

Explore the full profile